A large retrospective case-control study demonstrated that patients with high levels of auto-antibodies against HER2 have a decreased risk of developing both ductal carcinoma in-situ (DCIS) and IBC (Tabuchi et al., 2016). The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.